
Ind-Swift Labs. Sees Revision in Market Evaluation Amidst Challenging Fundamentals
2025-12-01 10:09:27Ind-Swift Labs., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in its fundamental and technical outlook. This adjustment highlights the evolving challenges the company faces amid a complex operating environment and fluctuating market sentiment.
Read MoreWhy is Ind-Swift Labs. falling/rising?
2025-11-26 01:02:09Recent Price Performance and Market Comparison Ind-Swift Laboratories has experienced a consistent decline over recent trading sessions, with the stock falling for two consecutive days and registering a cumulative loss of 6.5% during this period. The intraday low touched ₹93.5, marking a 2.35% drop from previous levels. This underperformance is further highlighted by the stock’s returns relative to the broader market indices. Over the past week, the stock declined by 2.84%, significantly lagging behind the Sensex’s marginal dip of 0.10%. The one-month performance is even more stark, with Ind-Swift Labs falling 7.78% while the Sensex gained 0.45%. Year-to-date figures reveal a 14.18% loss for the stock, contrasting sharply with the Sensex’s 8.25% gain. Technical indicat...
Read More
Ind-Swift Laboratories Q2 FY26: Recovery Momentum Stalls Amid Margin Pressures
2025-11-18 16:41:33Ind-Swift Laboratories Ltd., the Chandigarh-based active pharmaceutical ingredient (API) manufacturer, reported a consolidated net profit of ₹7.99 crores for Q2 FY26, marking an impressive 1848.78% year-on-year growth from ₹0.41 crores in Q2 FY25. However, the quarter-on-quarter picture reveals concerning trends, with net profit declining 8.89% from ₹8.77 crores in Q1 FY26. The micro-cap company, with a market capitalisation of ₹814.00 crores, has seen its stock price decline 2.91% to ₹96.90 as investors digest the mixed quarterly performance.
Read More
Ind-Swift Laboratories Faces Mixed Technical Trends Amid Recent Stock Evaluation Changes
2025-11-18 08:07:16Ind-Swift Laboratories, a microcap in the Pharmaceuticals and Biotechnology sector, has experienced a stock price decline amid mixed technical indicators. Recent performance shows a notable drop compared to the Sensex, with year-to-date losses contrasting with long-term gains, emphasizing the importance of monitoring market conditions.
Read More
Ind-Swift Laboratories Shows Stabilization Amidst Recent Financial Trend Adjustments
2025-11-18 08:00:18Ind-Swift Laboratories has experienced a flat financial performance for the quarter ending September 2025, with recent evaluations indicating stabilization in its metrics. The stock has shown volatility in trading, and while it has underperformed against the Sensex over the past year, it has outperformed over longer time frames.
Read MoreHow has been the historical performance of Ind-Swift Labs.?
2025-11-17 23:03:16Answer: The historical performance of Ind-Swift Labs shows significant fluctuations in key financial metrics over the years. Breakdown: Ind-Swift Labs experienced a notable decline in net sales from INR 1,709.15 crore in March 2024 to INR 561.71 crore in March 2025, following a peak of INR 1,207.31 crore in March 2023. The total operating income mirrored this trend, dropping to INR 561.71 crore in March 2025 from INR 1,709.15 crore in the previous year. The company's operating profit (PBDIT) also fell sharply, resulting in a loss of INR 19.39 crore in March 2025, compared to a profit of INR 303.06 crore in March 2024. Despite these challenges, profit before tax remained positive at INR 257.80 crore in March 2025, although it decreased from INR 598.22 crore in March 2024. The profit after tax for March 2025 was INR 250.53 crore, down from INR 539.24 crore the previous year. On the balance sheet, total liabi...
Read MoreWhy is Ind-Swift Labs. falling/rising?
2025-11-17 22:20:08As of 17-Nov, Ind-Swift Laboratories Ltd's stock price is currently at Rs 99.40, reflecting a decrease of Rs 4.5 or 4.33%. The stock has underperformed its sector by 4.61% today and has experienced a trend reversal after two consecutive days of gains. It reached an intraday low of Rs 99.1, indicating a significant drop of 4.62%. Additionally, the stock's performance over the past week shows a decline of 4.42%, and it has underperformed the benchmark Sensex, which has gained 1.69% during the same period. The delivery volume has also decreased by 14.86% compared to the five-day average, suggesting a decline in investor participation. Broader Market Context: In the context of the broader market, Ind-Swift Laboratories Ltd's year-to-date performance shows a decline of 9.39%, while the Sensex has risen by 8.72% during the same timeframe. This stark contrast highlights the stock's struggles compared to the overa...
Read MoreIs Ind-Swift Labs. technically bullish or bearish?
2025-11-17 08:05:52As of 14 November 2025, the technical trend has changed from sideways to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating bullish momentum. However, the weekly and monthly MACD and KST readings are mildly bearish, which suggests some caution. The Bollinger Bands show a bullish signal on the weekly timeframe but are mildly bearish on the monthly. Dow Theory indicates a mildly bullish stance on both weekly and monthly timeframes. Overall, the mixed signals from different indicators suggest a cautious bullish outlook....
Read More
Ind-Swift Laboratories Shows Mixed Technical Trends Amid Market Fluctuations
2025-11-17 08:00:58Ind-Swift Laboratories, a microcap in the Pharmaceuticals and Biotechnology sector, has seen its stock price rise slightly. The company has experienced fluctuations over the past year, with notable returns compared to the Sensex. Its performance over three years has significantly outpaced the index, indicating resilience in a competitive market.
Read MoreBoard Meeting Outcome for Outcome Of The Board Meeting Held On January 31 2026
31-Jan-2026 | Source : BSEOutcome for meeting held on January 31 2026 for the approval of inter alia unaudited financial results for the quarter and nine months ended December 31 2025.
Statement Of NIL Deviation For The Quarter Ended December 31 2025
31-Jan-2026 | Source : BSEPlease refer attached pdf.
Financial Results For The Quarter Ended December 31 2025 On Standalone And Consolidated Basis.
31-Jan-2026 | Source : BSEPlease refer the attached PDF.
Corporate Actions
No Upcoming Board Meetings
Ind-Swift Laboratories Ltd has declared 10% dividend, ex-date: 20 Sep 11
No Splits history available
No Bonus history available
No Rights history available